Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis

BACKGROUND: Hepatitis C virus (HCV) is a leading cause of liver cirrhosis and hepatocellular carcinoma globally. Sofosbuvir/velpatasvir (SOF/VEL) is an effective pan-genotypic direct-acting antiviral combination for treatment of chronic HCV infection. While the addition of ribavirin (RBV) to SOF/VEL...

Descripción completa

Detalles Bibliográficos
Autores principales: Loo, Jing Hong, Xu, Wen Xin Flora, Low, Jun Teck, Tay, Wei Xuan, Ang, Le Shaun, Tam, Yew Chong, Thurairajah, Prem Harichander, Kumar, Rahul, Wong, Yu Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258247/
https://www.ncbi.nlm.nih.gov/pubmed/35978662
http://dx.doi.org/10.4254/wjh.v14.i6.1248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258247/
https://www.ncbi.nlm.nih.gov/pubmed/35978662
http://dx.doi.org/10.4254/wjh.v14.i6.1248

Ejemplares similares